(FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | |
---|---|---|---|---|---|
Operating income | |||||
Operating expenses | |||||
Gross profit | |||||
Administrative expenses | -214.67%-136.67M | -83.43%-52.01M | 9.64%-43.43M | ---28.36M | ---48.06M |
Research and development expenses | -70.58%-311.57M | -57.34%-120.09M | -117.41%-182.65M | ---76.32M | ---84.01M |
Revaluation surplus | -2,346.62%-522.16M | -1,378.95%-399.64M | 123.65%23.24M | --31.25M | ---98.27M |
-Changes in the fair value of other assets | -2,346.62%-522.16M | -1,378.95%-399.64M | 123.65%23.24M | --31.25M | ---98.27M |
Special items of operating profit | 141.65%31.57M | 4,972.81%22.22M | -5.48%13.06M | ---456K | --13.82M |
Operating profit | -394.70%-938.83M | -643.72%-549.52M | 12.35%-189.78M | -73.89M | -216.52M |
Financing cost | 6.10%-400K | 7.37%-201K | 90.59%-426K | ---217K | ---4.53M |
Earning before tax | -393.80%-939.23M | -641.81%-549.72M | 13.95%-190.21M | -74.11M | -221.05M |
Tax | -137.50%-76K | 63.89%-26K | 66.67%-32K | ---72K | ---96K |
After-tax profit from continuing operations | -393.76%-939.31M | -641.12%-549.74M | 13.98%-190.24M | -74.18M | -221.15M |
Earning after tax | -393.76%-939.31M | -641.12%-549.74M | 13.98%-190.24M | -74.18M | -221.15M |
Profit attributable to shareholders | -393.76%-939.31M | -641.12%-549.74M | 13.98%-190.24M | -74.18M | -221.15M |
Basic earnings per share | -382.67%-3.62 | -639.43%-12.94 | 85.74%-0.75 | -1.75 | -5.26 |
Diluted earnings per share | -382.67%-3.62 | -639.43%-12.94 | 85.74%-0.75 | -1.75 | -5.26 |
Currency Unit | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
Auditor | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data